Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections
Acta Microbiologica et Immunologica Hungarica · 2025
DOI: 10.1556/030.2025.02676 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, 2025. Verfasst von Paiboon Vattanaviboon und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok 10210, Thailand. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Cephalosporins. Die Arbeit nennt 68 Literaturangaben. Gefördert von: Thailand Science Research and Innovation (TSRI), Chulabhorn Research Institute.
Abstract (Originalsprache)
Stenotrophomonas maltophilia has emerged as an opportunistic pathogen that causes life-threatening hospital-acquired infections. This microorganism possesses a diverse array of chromosome-encoded antimicrobial resistance genes, which render it inherently multidrug-resistant (MDR). Its ability to acquire additional antimicrobial resistance via mutations and the horizontal transfer of resistome elements from neighboring microbial communities has further contributed to the development of extensively drug-resistant (XDR) and even pandrug-resistant (PDR) strains. These strains are resistant to routinely used antibiotics, including the first-line drug trimethoprim/sulfamethoxazole as well as levofloxacin and minocycline. Recently, cefiderocol — a siderophore-conjugated cephalosporin — was developed for clinical use. This antibiotic has shown high in vitro efficacy against clinically relevant MDR gram-negative pathogens. Cefiderocol efficiently transverses the outer membrane of bacteria via iron transport systems and exhibits high stability against β-lactamases. An injectable form of cefiderocol has received Food and Drug Administration approval for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia caused by drug-resistant gram-negative bacteria. Clinical data on the use of cefiderocol for S. maltophilia infections remain limited, however, some in vitro , in vivo , and case studies have demonstrated its efficacy and successful treatment of MDR S. maltophilia infections. Given the narrow range of therapeutic options currently available, cefiderocol presents a promising alternative for the effective management of severe S. maltophilia infections. Nevertheless, the potential for the emergence of resistance remains a significant concern, as emerging evidence suggests that S. maltophilia may acquire resistance following exposure to this antibiotic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok 10210, Thailand.
- 2Center of Excellence on Environmental Health and Toxicology (EHT), Office of the Permanent Secretary (OPS), Ministry of Higher Education, Science, Research and Innovation (MHESI), Bangkok 10400, Thailand.
- 3Program in Applied Biological Sciences: Environmental Health, Chulabhorn Graduate Institute, Bangkok 10210, Thailand.
ORCID-Profile: Paiboon Vattanaviboon
Förderung
- Thailand Science Research and Innovation (TSRI), Chulabhorn Research Institute
Zitieren
APA
Vattanaviboon, P., Mongkolsuk, S., & Charoenlap, N. (2025). Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections. Acta Microbiologica et Immunologica Hungarica. https://doi.org/10.1556/030.2025.02676
Vancouver
Vattanaviboon P, Mongkolsuk S, Charoenlap N. Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections. Acta Microbiologica et Immunologica Hungarica. 2025. doi:10.1556/030.2025.02676
BibTeX
@article{Vattanaviboon2025,
author = {Vattanaviboon, Paiboon and Mongkolsuk, Skorn and Charoenlap, Nisanart},
title = {Cefiderocol as an alternative antibiotic therapy for treating severe Stenotrophomonas maltophilia infections},
journal = {Acta Microbiologica et Immunologica Hungarica},
year = {2025},
doi = {10.1556/030.2025.02676}
}
EUVIMED